Shockwave Medical Finds $35M For Cardiovascular Therapy
Fremont-based Shockwave Medical, a developer of technology to treat calcified plaque that contributes to cardiovascular disease, has raised $35M in an extension of its Series C funding, the company said today. The funding came from Fidelity Management & Research Company plus certain funds and accounts advised by T. Rowe Price Associates. The company said funding will go towards commercialization and advanced clinical development of its systems in the US and Europe. The earlier tranche of its Series C was worth $45M. Doug Godshall is President and CEO of Shockwave Medical.
posted on Tuesday, October 10, 2017 (Link to more information)
Related companies:
ShockWave Medical, Inc.
Related stories:
> Shockwave Medical Gets $45M In Series C
> Reflexion Medical Sees $11.6M For Medical Devices
> InCarda Therapeutics Finds $5M
> Viacom's MTV Buys Atom Entertainment
> Proteus Biomedical Raises $32M
silicontap.com Home